Search

everythinglearnresearchcommunity

for

Search:↓

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Genomic profiling for myeloid cancers can find important inherited mutations, but it's challenging when these mutations aren't related to the patient's symptoms.

The nano-carrier makes etoposide safer and more effective against lung cancer.

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Tofacitinib treatment is used for teenagers with alopecia areata.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Activating autophagy might reverse skin fibrosis.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.

Baricitinib is more effective than methotrexate for severe alopecia areata.

A special gel with medicine helps prevent melanoma from coming back after surgery.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Polyamines are crucial for skin tumor development, and inhibiting them can prevent tumors.

Sonidegib and vismodegib have different side effects and reporting patterns.

Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.

Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Non-myeloablative stem cell transplants are a promising, less toxic option for older or weaker patients, with fewer side effects and good outcomes.

Some heart drugs show promise for other conditions, but more research is needed to confirm their effectiveness and safety.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Mononuclear cells may protect against certain chemotherapy-induced hair loss.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.